Hubei Biocause Pharmaceutical Net Asset Quality Index
Hubei Biocause Pharmaceutical net asset quality index. Hubei Biocause Pharmaceutical (000627) has a Net Asset Quality Index of 12.6% as of September 2024. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥285.15 Billion minus total liabilities of CN¥249.15 Billion yields net assets of CN¥36.00 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See net assets of Hubei Biocause Pharmaceutical for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Hubei Biocause Pharmaceutical (2000–2023)
Net asset quality index of Hubei Biocause Pharmaceutical from 2000 to 2023. This chart shows how Hubei Biocause Pharmaceutical's Net Asset Quality Index has evolved across 24 annual periods from 2000 to 2023. As of September 2024, the index stands at 12.6%, representing net assets of CN¥36.00 Billion against total assets of CN¥285.15 Billion CNY. Check 000627 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Hubei Biocause Pharmaceutical Net Asset Quality Index by Year (2000–2023)
Hubei Biocause Pharmaceutical net asset quality index by year from 2000 to 2023. The table below presents the year-by-year Net Asset Quality Index for Hubei Biocause Pharmaceutical from 2000 to 2023, covering 24 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market cap of Hubei Biocause Pharmaceutical.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2023 | 11.1% | CN¥33.63 Billion | CN¥301.94 Billion | CN¥268.30 Billion | ▼ -0.9 pp |
| 2022 | 12.0% | CN¥34.60 Billion | CN¥288.60 Billion | CN¥254.00 Billion | ▼ -2.2 pp |
| 2021 | 14.2% | CN¥37.47 Billion | CN¥263.90 Billion | CN¥226.43 Billion | ▼ -0.2 pp |
| 2020 | 14.4% | CN¥34.59 Billion | CN¥239.40 Billion | CN¥204.81 Billion | ▼ -2.3 pp |
| 2019 | 16.7% | CN¥34.35 Billion | CN¥205.27 Billion | CN¥170.92 Billion | ▲ +2.1 pp |
| 2018 | 14.6% | CN¥26.01 Billion | CN¥178.25 Billion | CN¥152.24 Billion | ▼ -4.4 pp |
| 2017 | 19.0% | CN¥26.70 Billion | CN¥140.42 Billion | CN¥113.71 Billion | ▲ +1.7 pp |
| 2016 | 17.3% | CN¥20.40 Billion | CN¥117.88 Billion | CN¥97.48 Billion | ▼ -56.7 pp |
| 2015 | 74.0% | CN¥1.78 Billion | CN¥2.41 Billion | CN¥625.50 Million | ▲ +3.4 pp |
| 2014 | 70.7% | CN¥1.49 Billion | CN¥2.11 Billion | CN¥618.76 Million | ▲ +4.1 pp |
| 2013 | 66.6% | CN¥1.44 Billion | CN¥2.16 Billion | CN¥720.71 Million | ▼ -7.9 pp |
| 2012 | 74.5% | CN¥1.54 Billion | CN¥2.06 Billion | CN¥527.37 Million | ▼ -0.6 pp |
| 2011 | 75.1% | CN¥1.41 Billion | CN¥1.88 Billion | CN¥469.47 Million | ▼ -6.0 pp |
| 2010 | 81.1% | CN¥1.60 Billion | CN¥1.98 Billion | CN¥374.25 Million | ▲ +8.0 pp |
| 2009 | 73.0% | CN¥1.57 Billion | CN¥2.16 Billion | CN¥581.29 Million | ▼ -3.4 pp |
| 2008 | 76.4% | CN¥1.51 Billion | CN¥1.98 Billion | CN¥466.75 Million | ▲ +11.0 pp |
| 2007 | 65.4% | CN¥866.03 Million | CN¥1.32 Billion | CN¥458.52 Million | ▲ +3.4 pp |
| 2006 | 62.0% | CN¥723.71 Million | CN¥1.17 Billion | CN¥443.66 Million | ▼ -5.2 pp |
| 2005 | 67.2% | CN¥731.23 Million | CN¥1.09 Billion | CN¥356.70 Million | ▲ +0.3 pp |
| 2004 | 66.9% | CN¥723.91 Million | CN¥1.08 Billion | CN¥357.41 Million | ▲ +1.1 pp |
| 2003 | 65.9% | CN¥718.75 Million | CN¥1.09 Billion | CN¥372.22 Million | ▼ -4.6 pp |
| 2002 | 70.4% | CN¥768.02 Million | CN¥1.09 Billion | CN¥322.39 Million | ▼ -6.7 pp |
| 2001 | 77.1% | CN¥762.99 Million | CN¥989.09 Million | CN¥226.09 Million | ▲ +10.1 pp |
| 2000 | 67.1% | CN¥594.52 Million | CN¥886.33 Million | CN¥291.81 Million | — |